HIGHLIGHTS
- who: Azizul Hasan Aamir from the Department of Diabetes, Endocrinology and Metabolic Diseases, Khyber have published the research work: Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial, in the Journal: (JOURNAL)
- what: This study was aimed to establish the safety and efficacy of Empagliflozin (Group-A) versus standard care (Group-B) in Pakistani Muslim individuals with type 2 diabetes. Those who agreed to participate in the study were then provided a computer-generated random allocation number.
- how: Methods A multicenter randomized clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.